To coincide with the publication of our Annual Review, here are some of the key research milestones that our amazing supporters have helped fund.
The breast cancer drug tamoxifen could also be used to reduce the chances of some women developing the disease, showing that even research into older drugs can provide new ways to prevent and treat cancer.
We launched our revolutionary TRACERx study that will plot the evolution of lung tumours in real time. In a world first, our researchers will track the genetic changes in patients’ tumours, as the disease develops and – for some – becomes resistant to treatments.
We announced a groundbreaking trial for neuroblastoma – BEACON – which will find out the best treatment for children whose disease has returned. You can read more about the scientist behind the trial – Professor Andy Pearson – in this blog post.
A gene linked to the repair of damaged DNA could also protect against ovarian cancer.
A DNA de-tangling molecule emerged as an important protector against cancer. It unwinds DNA so that it can be copied, and our researchers have discovered how faults in this molecule could lead to several types of cancer.
Cambridge researchers pinpointed a molecule that could help spot aggressive and non-aggressive prostate tumours – information that’s vital in selecting tumours in need of immediate treatment and others that can be safely monitored.
In a first for childhood cancer, a new clinical trial set out to test a type of ‘molecular radiotherapy’ in children with neuroblastoma.
A team of scientists from our London Research Institute mapped the evolutionary diversity found in kidney cancer in unprecedented detail. We caught up with the lead researcher – Professor Charlie Swanton – to find out more about how tumours evolve.
The shape of an abnormal protein was linked to an aggressive type of lung cancer. The discovery could help doctors predict which patients will benefit from certain targeted treatments for the disease.
And, of course, there has to be an honourable mention for the thousands of people who picked up their phones to donate following the #nomakeupselfie trend.
An ambitious new clinical trial is looking to test personalised treatments for lung cancer. The Matrix trial is part of a new age of clinical trial design, offering opportunities to test multiple drugs in a single trial – watch the animation below to find out more.
These are just a small selection of the standout research moments from our year in review, achievements that have only been made possible via the generous donations from our supporters. So we want to take this opportunity to thank each and every one of you for your fantastic support.
To read more about our recent achievements take a look at our “Highlights of 2013” blog post, or head over to the annual review page on our website. And to stay up to date, you can subscribe to this blog, either via its RSS feed, or by typing your email address into the box in the right hand column.